EKF Diagnostics Holdings PLC
LSE:EKF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aditya Birla Money Ltd
NSE:BIRLAMONEY
|
IN |
|
P
|
Pernod Ricard SA
OTC:PDRDF
|
FR |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (10.3), the stock would be worth GBX32.62 (28% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8 | GBX25.5 |
0%
|
| 3-Year Average | 10.3 | GBX32.62 |
+28%
|
| 5-Year Average | 10.3 | GBX32.76 |
+28%
|
| Industry Average | 0 | GBX0.08 |
-100%
|
| Country Average | 0 | GBX0.06 |
-100%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
GBX91m
|
/ |
Jan 2026
£12.4m
|
= |
|
|
GBX91m
|
/ |
Dec 2026
£14m
|
= |
|
|
GBX91m
|
/ |
Dec 2027
£15.2m
|
= |
|
|
GBX91m
|
/ |
Dec 2028
£16.5m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
114.4m GBP | 8 | 53.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
159.2B USD | 13.8 | 25.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.7B USD | 45.6 | 60.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126B USD | 19.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.8B USD | 12.9 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
96.2B USD | 19.7 | 33.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.6B EUR | 11.1 | 19.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 24 | 44.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.1B USD | 30.8 | 43.5 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.3B USD | 10 | 25.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.5B USD | 11.3 | 15.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
EKF Diagnostics Holdings PLC
Glance View
EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.
